PDCD1 and neoplasm: There is evidence that blocking the PD-1 pathway alone or in combination with anti-CTLA-4 monoclonal antibody can produce antitumor effects in either NSCLC or SCLC, and combination therapy provides a larger tumor response; however, therapy-related toxicity also increases [62].